



Shield Therapeutics plc
("Shield" or the "Company" or the "Group")

Grant of Share Options

London, UK, 13 February 2025: Shield Therapeutics plc (LSE: STX), a commercial stage pharmaceutical company specialising in iron deficiency, announces that on 12 February 2025 it granted share awards in the form of options over ordinary shares in the capital of the Company ("Ordinary Shares") under Shield Therapeutics' Retention and Performance Share Plan ("RPSP") to the Group's Chief Executive Officer ("CEO") as part of his onboarding.

The following options have been granted to Anders Lundstrom, CEO, who is deemed a PDMR:

Name	Option Plan	Number of Ordinary Shares under Option	Vesting Date
Anders Lundstrom	RPSP	5,000,000	Three years from date of grant, subject to Mr Lundstrom remaining in office as at the date of vesting.

The proportion of total options awarded to Anders Lundstrom is approximately 0.5% of the total number of AIM securities in issue at this time.

Anders Lundstrom currently holds 10,000 ordinary shares in the Company.

1.	Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA")		
a)	Name	Anders Lundstrom	
2.	Reason for the notification		
a)	Position/status	Chief Executive Officer	
b)	Initial notification/ amendment	Initial Notification	
3.	Details of the Issuer		
a)	Name	Shield Therapeutics plc	
b)	LEI code	213800G74QWY15FC3W71	
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted		
a)	Description of the financial instrument	Options over new Ordinary Shares	
	Identification code	ISIN: GB00BYV81293	
b)	Nature of the transaction	Grant of awards over new Ordinary Shares under the Company's Retention and Performance Share Plan.	
c)	Price(s) and volumes(s)	2025 RPSP Award	
		Price (£)	Volume
		0.037	5,000,000
d)	Aggregated information - Aggregate volume	Awards granted over 5,000,000 shares in total	

	- Price	3.7p exercise price
e)	Date of the transaction	12 February 2025
f)	Place of the transaction	Outside of trading venue

For further information please contact:

Shield Therapeutics plc

Anders Lundstrom, CEO
Santosh Shanbhag, CFO
Stephanie Hicks, Investor Relations

www.shieldtherapeutics.com
+44 (0) 191 511 8500
Investorrelations@shieldtx.com

Nominated Adviser and Joint Broker

Peel Hunt LLP

James Steel / Patrick Birkholm

+44 (0)20 7418 8900

Joint Broker

+44 (0)20 7220 0500

Cavendish Ltd

Geoff Nash / Rory Sale / Nigel Birks / Harriet Ward

Financial PR & IR Advisor

Walbrook PR

Alice Woodings / Lianne Applegarth

+44 (0)20 7933 8780 or shield@walbrookpr.com

About Iron Deficiency and ACCRUFER®/FeRACCRU®

Clinically low iron levels (aka iron deficiency, ID) can cause serious health problems for adults of all ages, across multiple therapeutic areas. Together, ID and ID with anemia (IDA) affect about 20 million people in the US and represent a \$2.3B market opportunity. As the first and only FDA approved oral iron to treat ID/IDA, ACCRUFER® has the potential to meet an important unmet medical need for both physicians and patients.

ACCRUFER®/FeRACCRU® (ferric maltol) is a novel, stable, non-salt-based oral therapy for adults with ID/IDA. The drug has a novel mechanism of absorption compared to other oral iron therapies and has been shown to be an efficacious and well-tolerated therapy in a range of clinical trials. More information about ACCRUFER®/FeRACCRU®, including the product label, can be found at: www.accrufer.com and www.feraccru.com.

About Shield Therapeutics plc

Shield is a commercial stage specialty pharmaceutical company that delivers ACCRUFER®/FeRACCRU® (ferric maltol), an innovative and differentiated pharmaceutical product, to address a significant unmet need for patients suffering from iron deficiency, with or without anemia. The Company has launched ACCRUFER® in the U.S. with an exclusive, multi-year collaboration agreement with Viatrix Inc. Outside of the U.S., the Company has licensed the rights to four specialty pharmaceutical companies. FeRACCRU® is commercialized in the UK and European Union by Norgine B.V., which also has marketing rights in Australia and New Zealand. Shield also has an exclusive license agreement with Beijing Aosaikang Pharmaceutical Co., Ltd., for the development and commercialization of ACCRUFER®/ FeRACCRU® in China, Hong Kong, Macau and Taiwan, with Korea Pharma Co., Ltd. for the Republic of Korea, and with KYE Pharmaceuticals Inc. for Canada.

ACCRUFER®/FeRACCRU® has patent coverage until the mid-2030s.

ACCRUFER®/FeRACCRU® are registered trademarks of Shield Therapeutics.